Characterization of the metabolic activation of hepatitis C virus nucleoside inhibitor beta-D-2'-Deoxy-2'-fluoro-2'-C-methylcytidine (PSI-6130) and identification of a novel active 5'-triphosphate species. 2007

Han Ma, and Wen-Rong Jiang, and Nicole Robledo, and Vincent Leveque, and Samir Ali, and Teresa Lara-Jaime, and Mohammad Masjedizadeh, and David B Smith, and Nick Cammack, and Klaus Klumpp, and Julian Symons
Roche Palo Alto LLC, Palo Alto, California 94304, USA. han.ma@roche.com

beta-D-2'-Deoxy-2'-fluoro-2'-C-methylcytidine (PSI-6130) is a potent inhibitor of hepatitis C virus (HCV) replication in the subgenomic HCV replicon system, and its corresponding 5'-triphosphate is a potent inhibitor of the HCV RNA polymerase in vitro. In this study the formation of PSI-6130-triphosphate was characterized in primary human hepatocytes. PSI-6130 and its 5'-phosphorylated derivatives were identified, and the intracellular concentrations were determined. In addition, the deaminated derivative of PSI-6130, beta-d-2'-deoxy-2'-fluoro-2'-C-methyluridine (RO2433, PSI-6026) and its corresponding phosphorylated metabolites were identified in human hepatocytes after incubation with PSI-6130. The formation of the 5'-triphosphate (TP) of PSI-6130 (PSI-6130-TP) and RO2433 (RO2433-TP) increased with time and reached steady state levels at 48 h. The formation of both PSI-6130-TP and RO2433-TP demonstrated a linear relationship with the extracellular concentrations of PSI-6130 up to 100 mum, suggesting a high capacity of human hepatocytes to generate the two triphosphates. The mean half-lives of PSI-6130-TP and RO2433-TP were 4.7 and 38 h, respectively. RO2433-TP also inhibited RNA synthesis by the native HCV replicase isolated from HCV replicon cells and the recombinant HCV polymerase NS5B with potencies comparable with those of PSI-6130-TP. Incorporation of RO2433-5'-monophosphate (MP) into nascent RNA by NS5B led to chain termination similar to that of PSI-6130-MP. These results demonstrate that PSI-6130 is metabolized to two pharmacologically active species in primary human hepatocytes.

UI MeSH Term Description Entries
D008954 Models, Biological Theoretical representations that simulate the behavior or activity of biological processes or diseases. For disease models in living animals, DISEASE MODELS, ANIMAL is available. Biological models include the use of mathematical equations, computers, and other electronic equipment. Biological Model,Biological Models,Model, Biological,Models, Biologic,Biologic Model,Biologic Models,Model, Biologic
D008956 Models, Chemical Theoretical representations that simulate the behavior or activity of chemical processes or phenomena; includes the use of mathematical equations, computers, and other electronic equipment. Chemical Models,Chemical Model,Model, Chemical
D010710 Phosphates Inorganic salts of phosphoric acid. Inorganic Phosphate,Phosphates, Inorganic,Inorganic Phosphates,Orthophosphate,Phosphate,Phosphate, Inorganic
D010766 Phosphorylation The introduction of a phosphoryl group into a compound through the formation of an ester bond between the compound and a phosphorus moiety. Phosphorylations
D002478 Cells, Cultured Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others. Cultured Cells,Cell, Cultured,Cultured Cell
D002851 Chromatography, High Pressure Liquid Liquid chromatographic techniques which feature high inlet pressures, high sensitivity, and high speed. Chromatography, High Performance Liquid,Chromatography, High Speed Liquid,Chromatography, Liquid, High Pressure,HPLC,High Performance Liquid Chromatography,High-Performance Liquid Chromatography,UPLC,Ultra Performance Liquid Chromatography,Chromatography, High-Performance Liquid,High-Performance Liquid Chromatographies,Liquid Chromatography, High-Performance
D003841 Deoxycytidine A nucleoside component of DNA composed of CYTOSINE and DEOXYRIBOSE. Cytosine Deoxyribonucleoside,Cytosine Deoxyriboside,Deoxyribonucleoside, Cytosine,Deoxyriboside, Cytosine
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000998 Antiviral Agents Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. Antiviral,Antiviral Agent,Antiviral Drug,Antivirals,Antiviral Drugs,Agent, Antiviral,Agents, Antiviral,Drug, Antiviral,Drugs, Antiviral
D012321 DNA-Directed RNA Polymerases Enzymes that catalyze DNA template-directed extension of the 3'-end of an RNA strand one nucleotide at a time. They can initiate a chain de novo. In eukaryotes, three forms of the enzyme have been distinguished on the basis of sensitivity to alpha-amanitin, and the type of RNA synthesized. (From Enzyme Nomenclature, 1992). DNA-Dependent RNA Polymerases,RNA Polymerases,Transcriptases,DNA-Directed RNA Polymerase,RNA Polymerase,Transcriptase,DNA Dependent RNA Polymerases,DNA Directed RNA Polymerase,DNA Directed RNA Polymerases,Polymerase, DNA-Directed RNA,Polymerase, RNA,Polymerases, DNA-Dependent RNA,Polymerases, DNA-Directed RNA,Polymerases, RNA,RNA Polymerase, DNA-Directed,RNA Polymerases, DNA-Dependent,RNA Polymerases, DNA-Directed

Related Publications

Han Ma, and Wen-Rong Jiang, and Nicole Robledo, and Vincent Leveque, and Samir Ali, and Teresa Lara-Jaime, and Mohammad Masjedizadeh, and David B Smith, and Nick Cammack, and Klaus Klumpp, and Julian Symons
February 2008, Antimicrobial agents and chemotherapy,
Han Ma, and Wen-Rong Jiang, and Nicole Robledo, and Vincent Leveque, and Samir Ali, and Teresa Lara-Jaime, and Mohammad Masjedizadeh, and David B Smith, and Nick Cammack, and Klaus Klumpp, and Julian Symons
January 2006, Antiviral chemistry & chemotherapy,
Han Ma, and Wen-Rong Jiang, and Nicole Robledo, and Vincent Leveque, and Samir Ali, and Teresa Lara-Jaime, and Mohammad Masjedizadeh, and David B Smith, and Nick Cammack, and Klaus Klumpp, and Julian Symons
February 2007, Antimicrobial agents and chemotherapy,
Han Ma, and Wen-Rong Jiang, and Nicole Robledo, and Vincent Leveque, and Samir Ali, and Teresa Lara-Jaime, and Mohammad Masjedizadeh, and David B Smith, and Nick Cammack, and Klaus Klumpp, and Julian Symons
August 2005, Journal of medicinal chemistry,
Han Ma, and Wen-Rong Jiang, and Nicole Robledo, and Vincent Leveque, and Samir Ali, and Teresa Lara-Jaime, and Mohammad Masjedizadeh, and David B Smith, and Nick Cammack, and Klaus Klumpp, and Julian Symons
August 2010, Antimicrobial agents and chemotherapy,
Han Ma, and Wen-Rong Jiang, and Nicole Robledo, and Vincent Leveque, and Samir Ali, and Teresa Lara-Jaime, and Mohammad Masjedizadeh, and David B Smith, and Nick Cammack, and Klaus Klumpp, and Julian Symons
August 2007, Antimicrobial agents and chemotherapy,
Han Ma, and Wen-Rong Jiang, and Nicole Robledo, and Vincent Leveque, and Samir Ali, and Teresa Lara-Jaime, and Mohammad Masjedizadeh, and David B Smith, and Nick Cammack, and Klaus Klumpp, and Julian Symons
October 2010, Journal of medicinal chemistry,
Han Ma, and Wen-Rong Jiang, and Nicole Robledo, and Vincent Leveque, and Samir Ali, and Teresa Lara-Jaime, and Mohammad Masjedizadeh, and David B Smith, and Nick Cammack, and Klaus Klumpp, and Julian Symons
June 2011, Antimicrobial agents and chemotherapy,
Han Ma, and Wen-Rong Jiang, and Nicole Robledo, and Vincent Leveque, and Samir Ali, and Teresa Lara-Jaime, and Mohammad Masjedizadeh, and David B Smith, and Nick Cammack, and Klaus Klumpp, and Julian Symons
August 1983, Cancer research,
Han Ma, and Wen-Rong Jiang, and Nicole Robledo, and Vincent Leveque, and Samir Ali, and Teresa Lara-Jaime, and Mohammad Masjedizadeh, and David B Smith, and Nick Cammack, and Klaus Klumpp, and Julian Symons
February 1996, Antimicrobial agents and chemotherapy,
Copied contents to your clipboard!